The Full Wiki

More info on Entacapone

Entacapone: Wikis

  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Entacapone
Systematic (IUPAC) name
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
Identifiers
CAS number 130929-57-6
ATC code N04BX02
PubChem 5281081
DrugBank APRD00416
Chemical data
Formula C14H15N3O5 
Mol. mass 305.286 g/mol
Synonyms
  • (E)-a-cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
  • (E)-2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-(nitrophenyl)acrylamide
Pharmacokinetic data
Bioavailability 35%
Protein binding 98% (binds to serum albumin)
Metabolism Hepatic
Half life 0.4-0.7 hour
Excretion 90% feces, 10% urine
Therapeutic considerations
Pregnancy cat. C(US)
Legal status Prescription only, unscheduled (USA)
Routes Oral
 Yes check.svgY(what is this?)  (verify)

Entacapone (INN) (pronounced /ˌɛntəkəˈpoʊn/, /ɛnˈtækəpoʊn/) is a drug that functions as a catechol-O-methyl transferase (COMT) inhibitor. It is used in the treatment of Parkinson's disease.

When administered in conjunction with dopaminergic agents such as L-DOPA, entacapone prevents COMT from metabolizing L-DOPA into 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the periphery, which does not easily cross the blood brain barrier (BBB). Pharmacologically, entacapone is somewhat similar to carbidopa or benserazide, in that it is an inhibitor of an enzyme that converts L-DOPA into a compound that cannot cross the BBB. Carbidopa and benserazide inhibit aromatic L-amino acid decarboxylase, which converts L-DOPA into dopamine, which cannot cross the BBB.

Entacapone is a member of the class of drugs known as nitrocatechols.

The most frequent undesirable effects caused by entacapone relate to the increased effects of L-DOPA, such as involuntary movements (dyskinesias). These occur most frequently at the beginning of entacapone treatment. Others common side effects are gastrointestinal problems, including diarrhoea, nausea and abdominal pains. The substance may cause urine to turn reddish-brown. This is a harmless side effect and is not a cause for concern. In studies with entacapone, some people have reported experiencing a dry mouth.

Products

Entacapone is developed by Orion Pharma and marketed by Novartis under the trade name Comtan in the United States.

Stalevo is another Novartis medication that contains entacapone in combination with carbidopa and levodopa (active ingredients in Sinemet).

References

External links

  • [1] (fda website)
  • Comtan (manufacturer's website)
  • Stalevo (manufacturer's website)







Got something to say? Make a comment.
Your name
Your email address
Message